PURPOSE/OBJECTIVES: To measure the total amount of @entity786 ( @entity15082 ) excreted in the urine of @entity1 with @entity5 and their cohabitating family members seven days after @entity15082 administration.    . DESIGN: Biological monitoring.   . SETTING: Home setting with outpatients receiving chemo-therapy.   . SAMPLE: 8 @entity1 administered @entity15082 , 10 cohabitating family members, and 10 control @entity1 .   . METHODS: During the first seven days after @entity15082 administration, urine samples were collected from the @entity1 . The samples were analyzed for the unchanged form of @entity15082 using gas chromatography in tandem with mass spectroscopy.    . MAIN RESEARCH VARIABLES: @entity15082 levels.    . FINDINGS: @entity15082 was detected in 112 of 276 @entity1 urine samples. The last sample containing detectable @entity15082 levels was collected after more than 48 hours in 63% of the @entity1 , with a maximum length of five days post-treatment. In addition, 243 urine samples were collected from family members, and @entity15082 was detected in the samples of five family members (17-252 ng per member). @entity15082 was not detected in any control @entity1 .    . CONCLUSIONS: These findings indicate that family members in close contact with @entity1 receiving @entity15082 are at high risk for drug exposure as many as seven days post-treatment.    . IMPLICATIONS FOR NURSING: Nurses should educate @entity1 and their family members about preventing exposure to antineoplastic drugs in the home setting.   .

Secondary Exposure of Family Members to XXXX After Chemotherapy of Outpatients With Cancer: A Pilot Study.

@entity1 :: ('9606', 'Species') :: ['participants', 'patients', 'patient'] @entity15082 :: ('C048599', 'Chemical') :: ['CPA'] @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']
@entity786 :: (MESH:D003520,Chemical) :: ['Cyclophosphamide']
